This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Carey Danis & Lowe
Carey Danis & Lowe launches Mirena information webpage.
St. Louis, Missouri (PRWEB) February 20, 2013
To address the increasing number of adverse event reports associated with the use of the Mirena intrauterine device manufactured by Bayer(1), lawyers at Carey Danis & Lowe have launched a new website with useful information for individuals who may have used the Mirena IUD or know someone who has used the contraceptive device.
The new webpage has information about health complications associated with use of Bayer's Mirena IUD. In Carey Danis & Lowe's investigation into patients who have used the Mirena IUD, the most common health complications linked to use of the contraceptive device are the IUD embedding into the uterine wall, IUD tissue perforation, and ectopic pregnancy.(2)
The information provided on the Mirena IUD website is intended to assist patients who have used the IUD and individuals who know someone who has used the contraceptive device with understanding the IUD's health complications and exploring legal options offered by Carey Danis & Lowe.
In addition to launching a new Mirena IUD webpage, lawyers at Carey Danis & Lowe are closely watching a lawsuit filed against Bayer in a Pennsylvania federal court.
According to a Bloomberg News report,(3) a new Mirena IUD lawsuit has been filed against Bayer in the U.S. District Court for the Eastern District of Pennsylvania in Philadelphia. The plaintiff who filed the lawsuit alleges that Bayer Healthcare Pharmaceuticals, Inc. failed to supply information and warn the public and healthcare providers about the health problems associated with use of the Mirena IUD, including the device embedding into surrounding tissue and ectopic pregnancy among others.
The plaintiff in the case known as Prendergast v. Bayer Pharmaceuticals Corp. is a Pennsylvania women who received a Mirena IUD, and subsequently had surgery to remove the contraceptive device after experiencing serious complications.(3) Among her other claims in the lawsuit, Ms. Prendergast alleges that the German pharmaceutical company employed misleading and deceptive marketing to advertise the Mirena IUD as a safe medical device.
In response to the Pennsylvania Mirena IUD lawsuit, a Bayer spokesperson said that the pharmaceutical company "will vigorously defend itself against claims regarding Mirena”, according to Bloomberg News.
The Pennsylvania Mirena IUD lawsuit is not the first circumstance wherein Bayer's Mirena marketing campaign has fallen under scrutiny for its deceptive strategies. The U.S. Food and Drug Administration (FDA) in 2009 wrote a letter to a Bayer executive that pointed to unsubstantiated marketing language that claimed Mirena would improve happiness, health, and one's romantic life.(4)
In its letter, the FDA stated that no such evidence existed linking Mirena to health improvements, and in fact, they had evidence that demonstrated the opposite, that Mirena use led to a decline in health due to certain side effects. As a result of outrageous claims supported by no evidence of any kind, the FDA ruled that Bayer's Mirena marketing strategy violated the Federal Food, Drug, and Cosmetic Act.
To learn more about the serious health risks linked to use of Bayer's Mirena IUD, the Mirena deceptive advertising campaign, and legal options for those who have used the Mirena IUD, contact a lawyer at Carey Danis & Lowe, or visit the new Mirena IUD webpage.
Carey Danis & Lowe is a plaintiff's litigation firm based in St. Louis, Missouri with law offices across the United States in Illinois, Missouri, and Florida. Carey Danis & Lowe specializes in defective drug and pharmaceutical litigation and class action lawsuits. The Carey Danis & Lowe team is comprised of experienced attorneys working alongside knowledgeable professional staff that includes medical doctors, nurses, and information technology specialists. Contact Carey Danis & Lowe at 800-721-2519.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/2/prweb10447229.htm